{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:17:02Z","timestamp":1790223422794,"version":"4.1.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"14","funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","award":["16H04713"],"award-info":[{"award-number":["16H04713"]}],"id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17ck0106287h0001"],"award-info":[{"award-number":["17ck0106287h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["16cm0106301h0001"],"award-info":[{"award-number":["16cm0106301h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["15ck0106132h0002"],"award-info":[{"award-number":["15ck0106132h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The anti-CCR4 mAb, mogamulizumab, offers therapeutic benefit to patients with adult T-cell leukemia-lymphoma (ATL), but skin-related adverse events (AE) such as erythema multiforme occur frequently. The purpose of this study was to determine the mechanisms by which mogamulizumab causes skin-related AEs in patients with ATL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>We investigated whether autoantibodies were present in patients\u2019 sera using flow cytometry to determine binding to keratinocytes and melanocytes (n = 17), and immunofluorescence analysis of tissue sections. We analyzed the IgM heavy chain repertoire in peripheral blood mononuclear cells before and after mogamulizumab or other chemotherapy by next-generation sequencing (NGS; n = 16).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Autoantibodies recognizing human keratinocytes or melanocytes were found in the sera of 6 of 8 patients suffering from mogamulizumab-induced erythema multiforme. In one patient, complement-dependent cytotoxicity (CDC) mediated by autoantibodies against keratinocytes or melanocytes was proportionally related to the severity of the erythema multiforme. The presence of autoantibodies in the epidermis was confirmed in all biopsy specimens of mogamulizumab-induced erythema multiforme (n = 12). Furthermore, colocalization of autoantibodies and C1q, suggesting the activation of CDC, was observed in 67% (8\/12). In contrast, no autoantibody or C1q was found in ATL tumor skin lesions (n = 13). Consistent with these findings, NGS demonstrated that IgM germline genes had newly emerged and expanded, resulting in IgM repertoire skewing at the time of erythema multiforme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Mogamulizumab elicits autoantibodies playing an important role in skin-related AEs, possibly associated with regulatory T-cell depletion. This is the first report demonstrating the presence of skin-directed autoantibodies after mogamulizumab treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1078-0432.ccr-18-2575","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T15:35:17Z","timestamp":1556120117000},"page":"4388-4399","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma"],"prefix":"10.1158","volume":"25","author":[{"given":"Yui","family":"Suzuki","sequence":"first","affiliation":[{"name":"1R&D Division, Kyowa Hakko Kirin Co. Ltd., Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-3787","authenticated-orcid":false,"given":"Masato","family":"Saito","sequence":"additional","affiliation":[{"name":"1R&D Division, Kyowa Hakko Kirin Co. Ltd., Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ishii","sequence":"additional","affiliation":[{"name":"1R&D Division, Kyowa Hakko Kirin Co. Ltd., Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Urakawa","sequence":"additional","affiliation":[{"name":"1R&D Division, Kyowa Hakko Kirin Co. Ltd., Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"1R&D Division, Kyowa Hakko Kirin Co. Ltd., Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Masaki","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan."},{"name":"3Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahi","family":"Ito","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan."},{"name":"4Department of Tumor Immunology, Aichi Medical University School of Medicine, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Hiura","sequence":"additional","affiliation":[{"name":"1R&D Division, Kyowa Hakko Kirin Co. Ltd., Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-5883","authenticated-orcid":false,"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"1R&D Division, Kyowa Hakko Kirin Co. Ltd., Shizuoka, Japan."},{"name":"5Medical Affairs Department, Kyowa Hakko Kirin Co. Ltd., Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"6Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"3Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-0777","authenticated-orcid":false,"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan."},{"name":"7Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"2022061102063944700_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"key":"2022061102063944700_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984\u20131987)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"2022061102063944700_bib3","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022061102063944700_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrc2111","article-title":"Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation","volume":"7","author":"Matsuoka","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2022061102063944700_bib5","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"key":"2022061102063944700_bib6","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2022061102063944700_bib7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061102063944700_bib8","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-04-0983","article-title":"The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia\/lymphoma","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022061102063944700_bib9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022061102063944700_bib10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"2022061102063944700_bib11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"2022061102063944700_bib12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci"},{"key":"2022061102063944700_bib13","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci"},{"key":"2022061102063944700_bib14","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1158\/1078-0432.CCR-15-0357","article-title":"Phase Ia study of FoxP3+ CD4 treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients","volume":"21","author":"Kurose","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2022061102063944700_bib15","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061102063944700_bib16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1349-7006.2006.00307.x","article-title":"CCR4 as a novel molecular target for immunotherapy of cancer","volume":"97","author":"Ishida","year":"2006","journal-title":"Cancer Sci"},{"key":"2022061102063944700_bib17","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-NB2018-001","article-title":"Mogamulizumab tops standard of care for CTCL","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"2022061102063944700_bib18","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"2022061102063944700_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1704827","article-title":"Mogamulizumab (anti-CCR4) in HTLV-1-associated myelopathy","volume":"378","author":"Sato","year":"2018","journal-title":"N Engl J Med"},{"key":"2022061102063944700_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet"},{"key":"2022061102063944700_bib21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"2022061102063944700_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fimmu.2012.00211","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity","volume":"3","author":"Barzaghi","year":"2012","journal-title":"Front Immunol"},{"key":"2022061102063944700_bib23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/jid.2010.16","article-title":"Autoantibodies in scurfy mice and IPEX patients recognize keratin 14","volume":"130","author":"Huter","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2022061102063944700_bib24","doi-asserted-by":"crossref","first-page":"19042","DOI":"10.1073\/pnas.1313547110","article-title":"B cells are critical for autoimmune pathology in Scurfy mice","volume":"110","author":"Aschermann","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061102063944700_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2005.08.047","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature","volume":"55","author":"McGinness","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2022061102063944700_bib26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jim.2007.01.019","article-title":"Methods for comparing the diversity of samples of the T cell receptor repertoire","volume":"321","author":"Venturi","year":"2007","journal-title":"J Immunol Methods"},{"key":"2022061102063944700_bib27","doi-asserted-by":"crossref","first-page":"W34","DOI":"10.1093\/nar\/gkt382","article-title":"IgBLAST: an immunoglobulin variable domain sequence analysis tool","volume":"41","author":"Ye","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2022061102063944700_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12475","article-title":"Protection of host cells by complement regulators","volume":"274","author":"Schmidt","year":"2016","journal-title":"Immunol Rev"},{"key":"2022061102063944700_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/302575a0","article-title":"Somatic generation of antibody diversity","volume":"302","author":"Tonegawa","year":"1983","journal-title":"Nature"},{"key":"2022061102063944700_bib30","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"2022061102063944700_bib31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1084\/jem.20040920","article-title":"Bruton's tyrosine kinase (Btk) is essential for human B cell tolerance","volume":"200","author":"Ng","year":"2004","journal-title":"J Exp Med"},{"key":"2022061102063944700_bib32","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1172\/JCI45790","article-title":"The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans","volume":"121","author":"Menard","year":"2011","journal-title":"J Clin Invest"},{"key":"2022061102063944700_bib33","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.immuni.2008.09.015","article-title":"IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans","volume":"29","author":"Isnardi","year":"2008","journal-title":"Immunity"},{"key":"2022061102063944700_bib34","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1172\/JCI61788","article-title":"Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy","volume":"122","author":"Sauer","year":"2012","journal-title":"J Clin Invest"},{"key":"2022061102063944700_bib35","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2012-09-457465","article-title":"Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells","volume":"121","author":"Kinnunen","year":"2013","journal-title":"Blood"},{"key":"2022061102063944700_bib36","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0022-3476(05)81999-7","article-title":"Familial autoimmune enteropathy with circulating anti-bullous pemphigoid antibodies and chronic autoimmune hepatitis","volume":"125","author":"Lachaux","year":"1994","journal-title":"J Pediatr"},{"key":"2022061102063944700_bib37","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","article-title":"BP180 is critical in the autoimmunity of bullous pemphigoid","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"2022061102063944700_bib38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00403-012-1213-9","article-title":"Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients","volume":"304","author":"Quaglino","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"2022061102063944700_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jdv.12091","article-title":"Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid","volume":"28","author":"Antiga","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022061102063944700_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI0214643","article-title":"The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo","volume":"109","author":"Kemp","year":"2002","journal-title":"J Clin Invest"},{"key":"2022061102063944700_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(84)90084-9","article-title":"Antibodies to melanocytes in vitiligo","volume":"1","author":"Betterle","year":"1984","journal-title":"Lancet"},{"key":"2022061102063944700_bib42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"2022061102063944700_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional Treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"2022061102063944700_bib44","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/jid.2015.26","article-title":"CCL22 to activate treg migration and suppress depigmentation in vitiligo","volume":"135","author":"Eby","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2022061102063944700_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autrev.2014.10.002","article-title":"Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics","volume":"14","author":"Dwivedi","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2022061102063944700_bib46","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.4049\/jimmunol.170.4.2170","article-title":"Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3","volume":"170","author":"Tsunoda","year":"2003","journal-title":"J Immunol"},{"key":"2022061102063944700_bib47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/25\/14\/4388\/2051632\/4388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/25\/14\/4388\/2051632\/4388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T10:34:15Z","timestamp":1654943655000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/25\/14\/4388\/81610\/Mogamulizumab-Treatment-Elicits-Autoantibodies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":47,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2019,7,15]]},"published-print":{"date-parts":[[2019,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-2575","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.22470491.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6527582","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6527582.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22470491","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]}}}